Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | ESRRG | P62508 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ESRRB | O95718 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797701 | 0.83 | KCNH2 (0.75) | KCNH2ESRRGLMNAHRH3SIGMAR1 | |
| Bromide SCHEMBL13275917 | 0.82 | KCNH2 (0.72) | KCNH2ESRRGLMNAHRH3SIGMAR1 | |
| SCHEMBL10186973 | 0.79 | TAAR1 (0.61) | KCNH2SIGMAR1TAAR1 | |
| SCHEMBL15706263 | 0.79 | KCNH2 (0.48) | KCNH2LMNASIGMAR1NR1H4TSHR | |
| SCHEMBL12891007 | 0.78 | KCNH2 (0.58) | KCNH2ESRRGLMNAHRH3SIGMAR1 | |
| SCHEMBL25479321 | 0.78 | HRH3 (0.42) | HRH3SIGMAR1TAAR1 | |
| SCHEMBL7456580 | 0.78 | KCNH2 (0.59) | KCNH2ESRRGLMNASIGMAR1GRIA4 | |
| SCHEMBL25532733 | 0.77 | KCNH2 (0.56) | KCNH2ESRRGLMNAHRH3SIGMAR1 | |
| SCHEMBL25530539 | 0.77 | KCNH2 (0.51) | KCNH2ESRRGLMNASIGMAR1GRIA4 | |
| SCHEMBL25541354 | 0.77 | KCNH2 (0.56) | KCNH2ESRRGLMNAHRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, CD47 | KCNH2 4131/4885ESRRG 740/4885LMNA 2168/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | KCNH2 1953/4885ESRRG 3236/4885LMNA 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.